Quantbot Technologies LP Sells 9,013 Shares of Encompass Health Corporation $EHC

Quantbot Technologies LP lowered its position in shares of Encompass Health Corporation (NYSE:EHC) by 28.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,523 shares of the company’s stock after selling 9,013 shares during the quarter. Quantbot Technologies LP’s holdings in Encompass Health were worth $2,861,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EHC. Tectonic Advisors LLC grew its stake in Encompass Health by 1.6% during the third quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock worth $678,000 after buying an additional 82 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Encompass Health by 23.0% in the 3rd quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock worth $57,000 after acquiring an additional 84 shares in the last quarter. EP Wealth Advisors LLC grew its position in Encompass Health by 2.4% during the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after acquiring an additional 88 shares during the last quarter. Natural Investments LLC increased its holdings in Encompass Health by 1.2% during the 3rd quarter. Natural Investments LLC now owns 7,808 shares of the company’s stock valued at $991,000 after purchasing an additional 89 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its position in Encompass Health by 1.1% in the 3rd quarter. TD Private Client Wealth LLC now owns 8,216 shares of the company’s stock valued at $1,044,000 after purchasing an additional 91 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Price Performance

Encompass Health stock opened at $108.02 on Tuesday. The stock has a market cap of $10.87 billion, a price-to-earnings ratio of 19.50, a P/E/G ratio of 2.07 and a beta of 0.70. Encompass Health Corporation has a 12-month low of $92.53 and a 12-month high of $127.99. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.76. The business’s 50-day simple moving average is $103.88 and its 200 day simple moving average is $113.97.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 5th. The company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.17. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The company had revenue of $3.09 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the firm earned $1.17 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. As a group, research analysts anticipate that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st will be issued a dividend of $0.19 per share. The ex-dividend date is Wednesday, April 1st. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. Encompass Health’s payout ratio is currently 13.72%.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 150,000 shares of the stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total value of $16,746,000.00. Following the sale, the chief executive officer directly owned 377,070 shares in the company, valued at approximately $42,096,094.80. This trade represents a 28.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EHC. Zacks Research cut Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, January 18th. Finally, Barclays upped their target price on shares of Encompass Health from $150.00 to $153.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $143.29.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.